{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:45:32Z","timestamp":1773873932457,"version":"3.50.1"},"reference-count":265,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.compbiomed.2025.111120","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T06:35:27Z","timestamp":1759127727000},"page":"111120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"PA","title":["Advancement in hepatocellular carcinoma research: Biomarkers, therapeutics approaches and impact of artificial intelligence"],"prefix":"10.1016","volume":"198","author":[{"given":"Devraj","family":"Rajak","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1701-3172","authenticated-orcid":false,"given":"Priyanshu","family":"Nema","sequence":"additional","affiliation":[]},{"given":"Arvindra","family":"Sahu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5499-1562","authenticated-orcid":false,"given":"Satyamshyam","family":"Vishwakarma","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0874-1794","authenticated-orcid":false,"given":"Sushil K.","family":"Kashaw","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/14756366.2019.1698036","article-title":"Benzothiazole derivatives as anticancer agents","volume":"35","author":"Ali","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.111120_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.compbiomed.2025.111120_bib3","first-page":"108","article-title":"The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis","volume":"19","author":"Hassanipour","year":"2020","journal-title":"EXCLI J"},{"key":"10.1016\/j.compbiomed.2025.111120_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh","year":"2016","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.compbiomed.2025.111120_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JHC.S307962","article-title":"The mechanisms of HBV-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.compbiomed.2025.111120_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/bs.acr.2020.10.003","article-title":"Hepatitis C virus associated hepatocellular carcinoma","volume":"149","author":"Khatun","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.cgh.2017.05.015","article-title":"Early age hepatocellular carcinoma associated with hepatitis B infection in South America","volume":"15","author":"Chan","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.111120_bib10","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib11","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1002\/cncr.24687","article-title":"Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link","volume":"115","author":"Siegel","year":"2009","journal-title":"Cancer: Interdiscip. Int.. J. Am. Cancer Soc."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.510310211","article-title":"Early detection of hepatocellular carcinoma increases the chance of treatment: hongkong experience","volume":"31","author":"Yuen","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"issue":"23","key":"10.1016\/j.compbiomed.2025.111120_bib14","first-page":"1635","article-title":"Cell cycle regulators and human hepatocarcinogenesis","volume":"45","author":"Hui","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cgh.2022.06.032","article-title":"Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis","volume":"21","author":"Huang","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib16","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.compbiomed.2025.111120_bib17","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","article-title":"World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma","volume":"62","author":"de Martel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib18","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.cgh.2023.02.017","article-title":"Alcohol-associated liver disease: integrated management with alcohol use disorder","volume":"21","author":"Arab","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice","year":"2018","journal-title":"Clin. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib20","first-page":"2170","article-title":"Aflatoxins: a global concern for food safety, human health and their management","volume":"7","author":"Kumar","year":"2016","journal-title":"Front. Microbiol."},{"issue":"18","key":"10.1016\/j.compbiomed.2025.111120_bib21","doi-asserted-by":"crossref","first-page":"8586","DOI":"10.1073\/pnas.90.18.8586","article-title":"Aflatoxin B1 induces the transversion of G--T in codon 249 of the p53 tumor suppressor gene in human hepatocytes","volume":"90","author":"Aguilar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.compbiomed.2025.111120_bib22","first-page":"2170","article-title":"Aflatoxins: a global concern for food safety, human health and their management","volume":"7","author":"Kumar","year":"2016","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12291-017-0649-2","article-title":"Aflatoxins: implications on health","volume":"32","author":"Sarma","year":"2017","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.compbiomed.2025.111120_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrc4017","article-title":"Functional and genetic deconstruction of the cellular origin in liver cancer","volume":"15","author":"Marquardt","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.compbiomed.2025.111120_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"19","key":"10.1016\/j.compbiomed.2025.111120_bib26","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3748\/wjg.v25.i19.2279","article-title":"Mechanisms of hepatocellular carcinoma progression","volume":"25","author":"Ogunwobi","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","article-title":"A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma","volume":"75","author":"Donato","year":"1998","journal-title":"Int. J. Cancer [Internet]"},{"key":"10.1016\/j.compbiomed.2025.111120_bib28","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1038\/sj.onc.1206557","article-title":"Molecular viral oncology of hepatocellular carcinoma","volume":"22","author":"Block","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.compbiomed.2025.111120_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0741-8329(02)00212-4","article-title":"Monocyte activation in alcoholic liver disease","volume":"27","author":"McClain","year":"2002","journal-title":"Alcohol"},{"key":"10.1016\/j.compbiomed.2025.111120_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0741-8329(02)00215-X","article-title":"Ethanol, oxidative stress, and cytokine-induced liver cell injury","volume":"27","author":"Hoek","year":"2002","journal-title":"Alcohol"},{"key":"10.1016\/j.compbiomed.2025.111120_bib32","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/0140-6736(91)92236-U","article-title":"p53 mutation in hepatocellular carcinoma after aflatoxin exposure","volume":"338","author":"Ozturk","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.compbiomed.2025.111120_bib33","first-page":"2170","article-title":"Aflatoxins: a global concern for food safety, human health and their management","volume":"7","author":"Kumar","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib34","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1073\/pnas.0408824102","article-title":"Immune evasion by hepatitis C virus NS3\/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.compbiomed.2025.111120_bib35","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-14-2602","article-title":"Intratumor molecular and phenotypic diversity in hepatocellular carcinoma","volume":"21","author":"Nault","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic Muta tions and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/gutjnl-2017-315448","article-title":"beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids","volume":"68","author":"Senni","year":"2019","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib38","doi-asserted-by":"crossref","first-page":"11142","DOI":"10.3390\/ijms150611142","article-title":"Identification of drivers from cancer genome diversity in hepatocellular car cinoma","volume":"15","author":"Takai","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.compbiomed.2025.111120_bib39","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ng.903","article-title":"Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma","volume":"43","author":"Li","year":"2011","journal-title":"Nat. Genet."},{"issue":"16","key":"10.1016\/j.compbiomed.2025.111120_bib40","first-page":"5021","article-title":"Differential impact of telomere dysfunc tion on initiation and progression of hepatocellular carcinoma","volume":"63","author":"Farazi","year":"2003","journal-title":"Cancer Res."},{"issue":"1 Suppl","key":"10.1016\/j.compbiomed.2025.111120_bib41","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.jhep.2015.02.007","article-title":"Liver cancer: approaching a personalized care","volume":"62","author":"Bruix","year":"2015","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.111120_bib42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational land scape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.compbiomed.2025.111120_bib43","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocel lular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.111120_bib44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.compbiomed.2025.111120_bib45","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/sj.onc.1210279","article-title":"TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer","volume":"26","author":"Hussain","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.compbiomed.2025.111120_bib46","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-05-4608","article-title":"Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression","volume":"66","author":"Farazi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ijc.20279","article-title":"High \u03b1-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and \u03b2-catenin mutations","volume":"112","author":"Peng","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.compbiomed.2025.111120_bib48","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.20245","article-title":"Hepatitis B virus X protein is essential for the activation of Wnt\/\u03b2-catenin signaling in hepatoma cells","volume":"39","author":"Cha","year":"2004","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib49","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","article-title":"N6-methyladenosine modulates messenger RNA translation efficiency","volume":"161","author":"Wang","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib50","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.27198","article-title":"Genomic portrait of resectable hepatocel lular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification","volume":"60","author":"Ahn","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.compbiomed.2025.111120_bib51","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ng.2291","article-title":"Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators","volume":"44","author":"Fujimoto","year":"2012","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.compbiomed.2025.111120_bib52","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrc1934","article-title":"Hepatocellular carcinoma pathogenesis: from genes to environment","volume":"6","author":"Farazi","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib53","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/j.gastro.2018.11.001","article-title":"Genomic medicine and implications for hepatocellu lar carcinoma prevention and therapy","volume":"156","author":"Dhanasekaran","year":"2019","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.compbiomed.2025.111120_bib54","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.7150\/jca.26350","article-title":"The role of microRNAs in hepatocellular carcinoma","volume":"9","author":"Xu","year":"2018","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12253-019-00585-5","article-title":"Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage","volume":"26","author":"Luo","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"15","key":"10.1016\/j.compbiomed.2025.111120_bib56","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib57","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatol. Baltim. Md."},{"key":"10.1016\/j.compbiomed.2025.111120_bib58","article-title":"Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology","volume":"7","author":"Anugwom","year":"2021","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Metroticket investigator study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib60","doi-asserted-by":"crossref","first-page":"13621","DOI":"10.1128\/JVI.02016-12","article-title":"Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes","volume":"86","author":"Bose","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7150\/jca.16736","article-title":"Epithelial-mesenchymal transition is superior to vessels-encapsulate tumor cluster in promoting metastasis of hepatocellular carcinoma: a morphological evidence","volume":"8","author":"He","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.compbiomed.2025.111120_bib62","first-page":"90","article-title":"Radiomics based on artificial intelligence in liver diseases: where we are? Gastroenterol","volume":"8","author":"Hu","year":"2020","journal-title":"Rep"},{"key":"10.1016\/j.compbiomed.2025.111120_bib63","doi-asserted-by":"crossref","unstructured":"S. Lewis, S. Hectors, B. Taouli, Radiomics of hepatocellular carcinoma, Abdom. Radiol. (New York), 46 (1) (2021) 111\u2013123. Available at: https:\/\/doi.org\/10.1007\/s00261-019-02378-5.","DOI":"10.1007\/s00261-019-02378-5"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3350\/cmh.2018.0090","article-title":"Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update","volume":"25","author":"Kim","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib65","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2147\/JHC.S268288","article-title":"Up-to-date role of CT\/MRI LI-RADS in hepatocellular carcinoma","volume":"8","author":"Moura","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.compbiomed.2025.111120_bib66","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1007\/s00261-021-03100-0","article-title":"Imaging of treatment response during systemic therapy for hepatocellular carcinoma","volume":"46","author":"Masch","year":"2021","journal-title":"Abdom. Radiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00261-017-1292-3","article-title":"Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ","volume":"43","author":"Tang","year":"2018","journal-title":"Abdom. Radiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.680691","article-title":"Accuracy of various forms of contrast-enhanced MRI for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40644-020-00297-z","article-title":"A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver","volume":"20","author":"Nie","year":"2020","journal-title":"Cancer Imaging"},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib70","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0168-8278(03)00349-0","article-title":"Screening for hepatocellular carcinoma in cirrhosis","volume":"39","author":"Bolondi","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib71","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/jcm10050903","article-title":"Ultrasound or sectional imaging techniques as screening tools for hepatocellular carcinoma: fall forward or move forward?","volume":"10","author":"Sparchez","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1478-3231.2004.0903.x","article-title":"Hepatocellular carcinomas <2 Cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients","volume":"24","author":"Rapaccini","year":"2004","journal-title":"Liver Int. [Internet]"},{"key":"10.1016\/j.compbiomed.2025.111120_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10396-020-01012-y","article-title":"Current role of ultrasound in the diagnosis of hepatocellular carcinoma","volume":"47","author":"Tanaka","year":"2020","journal-title":"J. Med. Ultrason."},{"key":"10.1016\/j.compbiomed.2025.111120_bib74","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJMra0909487","article-title":"Point-of-care ultrasonography","volume":"364","author":"Moore","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib75","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/jum.14860","article-title":"Enhanced point-of-care ultrasound applications by integrating automated feature-learning systems using deep learning","volume":"38","author":"Shokoohi","year":"2019","journal-title":"J. Ultrasound Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib76","article-title":"Len vatinib for hepatocellular carcinoma: from preclinical mecha nisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.compbiomed.2025.111120_bib77","first-page":"1","article-title":"Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility","volume":"7","author":"Ferr\u00edn","year":"2015","journal-title":"Hepatic Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib78","unstructured":"."},{"key":"10.1016\/j.compbiomed.2025.111120_bib79","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/859076","article-title":"Biomarkers for hepatocellular carcinoma","volume":"2012","author":"Behne","year":"2012","journal-title":"Int. J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the early diagnosis of hepatocellular carcinoma","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis."},{"key":"10.1016\/j.compbiomed.2025.111120_bib81","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.3390\/ijms23052801","article-title":"Dickkopf-1 promotes angiogenesis and is a biomarker for hepatic stem cell-like hepatocellular carcinoma","volume":"23","author":"Suda","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2025.111120_bib82","first-page":"121","article-title":"An update of biochemical markers of hepatocellular carcinoma","volume":"10","author":"AlSalloom","year":"2016","journal-title":"Int. J. Health Sci."},{"key":"10.1016\/j.compbiomed.2025.111120_bib83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/carcin\/bgs372","article-title":"Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.compbiomed.2025.111120_bib84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fmolb.2020.00060","article-title":"Heat shock protein 60 in hepatocellular carcinoma: insights and perspectives","volume":"7","author":"Hoter","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.compbiomed.2025.111120_bib85","doi-asserted-by":"crossref","first-page":"9449","DOI":"10.1038\/s41598-017-09691-3","article-title":"Serum fibronectin distinguishes the early stages of hepatocellular carcinoma","volume":"7","author":"Kim","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2025.111120_bib86","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.cca.2011.08.029","article-title":"Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma","volume":"412","author":"Attallah","year":"2011","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"10.1016\/j.compbiomed.2025.111120_bib87","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.7150\/jca.20480","article-title":"Osteopontin-- a promising biomarker for cancer therapy","volume":"8","author":"Wei","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.compbiomed.2025.111120_bib88","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/jgh.12166","article-title":"Novel des--carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma","volume":"28","author":"Tanaka","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib89","article-title":"Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis","volume":"7","author":"Carr","year":"2021","journal-title":"J. Transl. Sci."},{"key":"10.1016\/j.compbiomed.2025.111120_bib90","first-page":"296","article-title":"Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas","volume":"9","author":"Long","year":"2010","journal-title":"Hepatobiliary Pancreat. Dis. Int. HBPD INT"},{"key":"10.1016\/j.compbiomed.2025.111120_bib91","article-title":"The applicability of ADA, AFU, and LAC in the early diagnosis and disease risk assessment of hepatitis B-Associated liver cirrhosis and hepatocellular carcinoma","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib92","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","article-title":"Immunomodulatory TGF-signaling in hepatocellular carcinoma","volume":"25","author":"Chen","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib93","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7314\/APJCP.2015.16.2.613","article-title":"Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma","volume":"16","author":"Elmashad","year":"2015","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.compbiomed.2025.111120_bib94","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjc.6605017","article-title":"Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis","volume":"100","author":"Schoenleber","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.compbiomed.2025.111120_bib95","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mc.10103","article-title":"Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma","volume":"36","author":"Daveau","year":"2003","journal-title":"Mol. Carcinog."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib96","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcmgh.2017.05.004","article-title":"Identification of the consistently altered metabolic targets in human hepatocellular carcinoma","volume":"4","author":"Nwosu","year":"2017","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib97","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiomed.2025.111120_bib98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.compbiomed.2025.111120_bib99","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/sj.onc.1209550","article-title":"New therapies for hepatocellular carcinoma","volume":"25","author":"Avila","year":"2006","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.compbiomed.2025.111120_bib100","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/hep.24216","article-title":"Increased RNA-Induced silencing complex (RISC) activity contributes to hepatocellular carcinoma","volume":"53","author":"Yoo","year":"2011","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.compbiomed.2025.111120_bib101","doi-asserted-by":"crossref","first-page":"13952","DOI":"10.1074\/jbc.M111.321646","article-title":"Multifunction protein staphylococcal nuclease domain contain ing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor \u03baB and miR-221","volume":"287","author":"Santhekadur","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.compbiomed.2025.111120_bib102","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cells8091075","article-title":"Roles of mTOR signaling in tissue regeneration","volume":"8","author":"Wei","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.compbiomed.2025.111120_bib103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"Ben-Sahra","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib104","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/cells9030746","article-title":"Elevated PDK1 expres sion drives PI3K\/AKT\/MTOR signaling promotes radiation resistant and dedifferentiated phenotype of hepatocellular carcinoma","volume":"9","author":"Bamodu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.compbiomed.2025.111120_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108990","article-title":"Small molecules from natural products targeting the Wnt\/\u03b2-catenin pathway as a therapeutic strategy","volume":"117","author":"Liu","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib106","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.22580","article-title":"Molecu lar mechanisms of hepatocellular carcinoma","volume":"48","author":"Aravalli","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib107","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/0976-9668.107276","article-title":"Influence of limonin on Wnt signalling molecule in HepG2 cell lines","volume":"4","author":"Langeswaran","year":"2013","journal-title":"J. Nat. Sci. Biol. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib108","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/bs.pmbts.2017.11.006","article-title":"Of wnts and ribosomes","volume":"153","author":"Pfister","year":"2018","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib109","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41556-019-0330-5","article-title":"EGFR is required for Wnt9a-Fzd9b signalling specificity in haematopoietic stem cells","volume":"21","author":"Grainger","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.111120_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152695","article-title":"Diverse basis of \u03b2-catenin activation in human hepatocellular carcinoma: implications in biology and prognosis","volume":"11","author":"Okabe","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib111","article-title":"Promotion of growth factor signaling as a critical function of \u03b2-catenin during HCC progression","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib112","article-title":"JAK\/STAT signaling in hepatocellular carcinoma","volume":"7","author":"Hin","year":"2020","journal-title":"Hepat. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/cr.2010.183","article-title":"NF-\u03baB and STAT3- key players in liver inflammation and cancer","volume":"21","author":"He","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib114","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","article-title":"The potential and controversy of targeting STAT family members in cancer","volume":"60","author":"Verhoeven","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.111120_bib115","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2011.06.005","article-title":"Targeting STAT3 in hepatocellular carcinoma: Sorafenib again","volume":"55","author":"Rosmorduc","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib116","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-015-0229-3","article-title":"Long noncoding RNA lncTCF7, induced by IL-6\/STAT3 transactivation, promotes hepatocel lular carcinoma aggressiveness through epithelial-mesenchymal transition","volume":"34","author":"Wu","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","volume":"113","author":"Thomas","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.compbiomed.2025.111120_bib118","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERKsignalling: a master reg ulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib119","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.compbiomed.2025.111120_bib120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semcdb.2016.06.007","article-title":"Ras signaling through RASSF proteins","volume":"58","author":"Donninger","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib121","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JHC.S224471","article-title":"Angiogenesis in hepatocellular carcinoma; pathophysiology, targeted therapy, and role of imaging","volume":"7","author":"Moawad","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"8","key":"10.1016\/j.compbiomed.2025.111120_bib122","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.bbamcr.2007.05.001","article-title":"Raf kinases: function, regulation and role in human cancer","volume":"1773","author":"Leicht","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.compbiomed.2025.111120_bib123","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1007\/s13277-015-4049-z","article-title":"HMGB1 promotes HCC progression partly by downregulating p21 via ERK\/c-Myc pathway and upregulating MMP-2","volume":"37","author":"Chen","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib124","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: the BCLC update and future prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.compbiomed.2025.111120_bib125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-018-0109-6","article-title":"Emerging therapies in advanced hepatocellular carcinoma","volume":"7","author":"Medavaram","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib126","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib127","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"issue":"70","key":"10.1016\/j.compbiomed.2025.111120_bib128","first-page":"571","article-title":"Bowel injury associated with liver surgery for hepatocellular carcinoma","volume":"53","author":"Tanaka","year":"2006","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib129","first-page":"16","article-title":"Updates in the management of hepatocellular carcinoma","volume":"7","author":"Wong","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver dis eases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"11 Suppl 1","key":"10.1016\/j.compbiomed.2025.111120_bib131","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1007\/s001470050459","article-title":"Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization","author":"Colella","year":"1998","journal-title":"Transpl. Int."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.111120_bib132","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib133","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib134","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"Suppl 1","key":"10.1016\/j.compbiomed.2025.111120_bib135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference","volume":"73","author":"Llovet","year":"2021","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.111120_bib136","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/lt.20526","article-title":"A prospective study on downstag ing of hepatocellular carcinoma prior to liver transplantation","volume":"11","author":"Yao","year":"2005","journal-title":"Liver Transplant."},{"key":"10.1016\/j.compbiomed.2025.111120_bib137","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2021.07.048","article-title":"National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States","volume":"20","author":"Kwong","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib138","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","article-title":"Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients","volume":"131","author":"Takayasu","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib139","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1148\/radiol.11081489","article-title":"Transcatheter intraarterial therapies: rationale and overview","volume":"259","author":"Lewandowski","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib140","doi-asserted-by":"crossref","first-page":"8165","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2025.111120_bib141","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4254\/wjh.v7.i5.738","article-title":"Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives","volume":"7","author":"Mosconi","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib142","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jvir.2018.03.018","article-title":"Radioembolization for hepatocellular carcinoma: a nationwide 10-Year experience","volume":"29","author":"Tohme","year":"2018","journal-title":"J. Vasc. Intervent. Radiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib143","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo-20-507","article-title":"The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure","volume":"12","author":"Ahmed","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib144","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00330-008-1211-7","article-title":"Yttrium-90 micro sphere radioembolization for the treatment of liver malignancies: a structured meta-analysis","volume":"19","author":"Vente","year":"2009","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4254\/wjh.v14.i5.885","article-title":"Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma","volume":"14","author":"Zane","year":"2022","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib146","article-title":"Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model","volume":"94","author":"Pillai","year":"2015","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.compbiomed.2025.111120_bib147","doi-asserted-by":"crossref","first-page":"HEP07","DOI":"10.2217\/hep-2018-0001","article-title":"Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review","volume":"5","author":"Galanakis","year":"2018","journal-title":"Hepat. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib148","article-title":"Radiofrequency ablation vs surgical resection for small unifocal hepatocellular carcinomas","volume":"93","author":"Lei","year":"2014","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.compbiomed.2025.111120_bib149","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/02656736.2015.1127434","article-title":"Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta- analysis","volume":"32","author":"Facciorusso","year":"2016","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.compbiomed.2025.111120_bib150","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/hep.30406","article-title":"Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers","volume":"70","author":"Bale","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib151","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-230X-11-143","article-title":"Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma","volume":"11","author":"HirokiNishikawa","year":"2011","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib152","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1148\/radiol.2015142151","article-title":"Microwave ablation: comparison of simultaneous and sequential activation of multiple antennas in liver model systems","volume":"278","author":"Harari","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib153","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00261-016-0662-6","article-title":"Microwave ablation for liver tumors","volume":"41","author":"Dou","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.compbiomed.2025.111120_bib154","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4292\/wjgpt.v7.i4.477","article-title":"Local ablative treatments for hepatocellular carcinoma: an updated review","volume":"7","author":"Facciorusso","year":"2016","journal-title":"World J. Gastrointest. Pharmacol. Therapeut"},{"key":"10.1016\/j.compbiomed.2025.111120_bib155","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1148\/rg.345140054","article-title":"Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation--what should you use and why?","volume":"34","author":"Hinshaw","year":"2014","journal-title":"Radiographics"},{"key":"10.1016\/j.compbiomed.2025.111120_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102016","article-title":"Immunotherapy for pancreatic cancer: a 2020 update","volume":"86","author":"Schizas","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.compbiomed.2025.111120_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12103025","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives","volume":"12","author":"Federico","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.compbiomed.2025.111120_bib158","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14712598.2020.1749593","article-title":"Nivolumab for the treatment of hepatocellular carcinoma","volume":"20","author":"Chiew Woon","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.compbiomed.2025.111120_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2022.151284","article-title":"Immunotherapeutic approaches in hepatocellular car cinoma: building blocks of hope in near future","volume":"102","author":"Minaei","year":"2023","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib160","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrat ing immunity's roles in cancersuppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.compbiomed.2025.111120_bib161","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immuno suppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib162","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibi-tor therapy: clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"issue":"17","key":"10.1016\/j.compbiomed.2025.111120_bib163","first-page":"32287","article-title":"Targets for immunotherapy of liver cancer","volume":"S0168\u20138278","author":"Greten","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib164","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","article-title":"ImmunobiologyandimmunotherapyofHCC:Spotlightoninnateandinnate-like immune cells","volume":"18","author":"Ruf","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.111120_bib165","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/hep.27246","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatol (Baltimore Md)"},{"key":"10.1016\/j.compbiomed.2025.111120_bib166","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.002","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"470","author":"Zongyi","year":"2020","journal-title":"Cancer Lett."},{"issue":"15","key":"10.1016\/j.compbiomed.2025.111120_bib167","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/CM9.0000000000003060","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"137","author":"Wang","year":"2024","journal-title":"Chin. Med. J. (Engl. Ed.)"},{"issue":"11","key":"10.1016\/j.compbiomed.2025.111120_bib168","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib169","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2147\/PPA.S296747","article-title":"Adherence to adjuvant tamoxifen in Mexican young women with breast cancer","volume":"15","author":"Martinez-Cannon","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.compbiomed.2025.111120_bib170","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/intimm\/dxab052","article-title":"Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies","volume":"33","author":"Watanabe","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib171","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","article-title":"Clinical practice. Chronic hepatitis C infection","volume":"364","author":"Rosen","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib172","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-016-1800-2","article-title":"TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors","volume":"65","author":"Spear","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.compbiomed.2025.111120_bib173","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.compbiomed.2025.111120_bib174","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14712598.2020.1819978","article-title":"Emerging vistas in CAR T-cell therapy: chal lenges and opportunities in solid tumors","volume":"21","author":"Date","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.compbiomed.2025.111120_bib175","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing chi meric antigen receptor T-cell efficacy in solid tumors","volume":"26","author":"Fuc\u00e0","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib176","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib177","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib178","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14737140.2021.1882855","article-title":"Advances in systemic therapy for the first-line treatment of unresectable HCC","volume":"21","author":"Vogel","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.compbiomed.2025.111120_bib179","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/14737140.2018.1535315","article-title":"Nivolumab for the treatment of hepatocellular carcinoma","volume":"18","author":"Finkelmeier","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.compbiomed.2025.111120_bib180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.compbiomed.2025.111120_bib181","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/fon-2018-0822","article-title":"Ramucirumab and its use in the treatment of hepatocellular carcinoma","volume":"15","author":"Turkes","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib182","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.compbiomed.2025.111120_bib183","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib184","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib185","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jcyt.2018.06.002","article-title":"Effect of dendritic cell\u2013based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis","volume":"20","author":"Chen","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.compbiomed.2025.111120_bib186","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1940-6207.CAPR-10-0040","article-title":"Vaccine prevention of cancer: can endogenous antigens be targeted?","volume":"3","author":"Weiner","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib187","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2019027047","article-title":"Nanoparticulate carriers used as vaccine adjuvant delivery systems","volume":"36","author":"Wang","year":"2019","journal-title":"Crit. Rev. \u2122 Ther. Drug Carr. Syst."},{"key":"10.1016\/j.compbiomed.2025.111120_bib188","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a Glypican-3\u2013Derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall SurvivalPhase I trial of GPC3 peptide vaccine in HCC patients","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib189","series-title":"Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients with Hepatocellular Carcinoma","author":"Rizell","year":"2013"},{"key":"10.1016\/j.compbiomed.2025.111120_bib190","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiomed.2025.111120_bib191","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib192","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.compbiomed.2025.111120_bib193","article-title":"Potential biomarkers for liver cancer diagnosis based on multi-omics strategy","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.111120_bib194","first-page":"333","article-title":"Metabolomics in cancer research and emerging applications in clinical oncology","volume":"71","author":"Schmidt","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.compbiomed.2025.111120_bib195","article-title":"Metabolomics in hepatocellular carcinoma: from biomarker discovery to precision medicine","volume":"4","author":"WuX","year":"2023","journal-title":"Front. Med. Technol."},{"issue":"39","key":"10.1016\/j.compbiomed.2025.111120_bib196","doi-asserted-by":"crossref","first-page":"63437","DOI":"10.18632\/oncotarget.11521","article-title":"Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.compbiomed.2025.111120_bib197","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-biochem-061516-044952","article-title":"Metabolite measurement: pitfalls to avoid and practices to follow","volume":"86","author":"Lu","year":"2017","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.111120_bib198","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11901-020-00553-7","article-title":"Genomic landscape of HCC","volume":"19","author":"Nia","year":"2020","journal-title":"Curr. Hepat. Rep."},{"key":"10.1016\/j.compbiomed.2025.111120_bib199","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1742-7843.2006.pto_391.x","article-title":"Pro teomics: recent applications and new technologies","volume":"98","author":"Elrick","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib200","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jhep.2022.01.014","article-title":"Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma","volume":"76","author":"Calderaro","year":"2022","journal-title":"J. Hepatol. [Internet]"},{"key":"10.1016\/j.compbiomed.2025.111120_bib201","article-title":"Artificial intelligence in drug design: algorithms, applications, challenges and ethics","volume":"3","author":"Alya","year":"2021","journal-title":"Future Drug Discov."},{"key":"10.1016\/j.compbiomed.2025.111120_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106324","article-title":"CADD, AI and ML in drug discovery: a comprehensive review","volume":"181","author":"Vemula","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.compbiomed.2025.111120_bib203","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-020-0232-8","article-title":"Impact of a deep learning assistant on the histopathologic classification of liver cancer","volume":"3","author":"Kiani","year":"2020","journal-title":"npj Digit. Med."},{"issue":"S1","key":"10.1016\/j.compbiomed.2025.111120_bib204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12920-021-00957-4","article-title":"Robust biomarker discovery for hepatocellular carcinoma from high-throughput data by multiple feature selection methods","volume":"14","author":"Zhang","year":"2021","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.compbiomed.2025.111120_bib205","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.691746","article-title":"Is health contagious?\u2014Based on empirical evidence from China family panel studies' data","volume":"9","author":"Hu","year":"2021","journal-title":"Front. Public Health"},{"key":"10.1016\/j.compbiomed.2025.111120_bib206","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221095946","article-title":"Artificial intelligence and machine learning in cancer research: a systematic and thematic analysis of the top 100 cited articles indexed in scopus database","volume":"29","author":"Musa","year":"2022","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib207","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10462-021-10034-y","article-title":"The role of AI technology in prediction, diagnosis and treatment of colorectal cancer","volume":"55","author":"Yu","year":"2022","journal-title":"Artif. Intell. Rev."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.111120_bib208","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4103\/ijc.IJC_399_20","article-title":"Artificial intelligence in cancer diagnostics and therapy: current perspectives","volume":"58","author":"Majumder","year":"2021","journal-title":"Indian J. Cancer"},{"issue":"10","key":"10.1016\/j.compbiomed.2025.111120_bib209","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00066-020-01626-8","article-title":"Applications of radiomics and machine learning for radiotherapy of malignant brain tumors","volume":"196","author":"Kocher","year":"2020","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/bib\/bbw114","article-title":"Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences","volume":"19","author":"Manzoni","year":"2018","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.compbiomed.2025.111120_bib211","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-019-0240-9","article-title":"Harnessing big \u2018omics\u2019 data and AI for drug discovery in hepatocellular carcinoma","volume":"17","author":"Chen","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib212","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nm843","article-title":"Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning","volume":"9","author":"Ye","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib213","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2147\/JMDH.S410301","article-title":"Machine learning and AI in cancer prognosis, prediction, and treatment selection: a critical approach","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Multidiscip. Healthc."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.111120_bib214","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017","volume":"5","author":"Global Burden of Disease Cancer Collaboration","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.111120_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189016","article-title":"Protein induced by vitamin K absence or antagonist II: experience to date and future directions","volume":"1878","author":"Dong","year":"2023","journal-title":"Biochim. Biophys. Acta, Rev. Cancer"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib216","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1158\/2159-8290.CD-24-1215","article-title":"NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma","volume":"15","author":"Lindblad","year":"2025","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.111120_bib217","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1097\/JS9.0000000000000729","article-title":"Incorporation of protein induced by vitamin K absence or antagonist-II into transplant criteria expands beneficiaries of liver transplantation for hepatocellular carcinoma: a multicenter retrospective cohort study in China","volume":"109","author":"Wang","year":"2023","journal-title":"Int. J. Surg."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.111120_bib218","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(23)00468-0","article-title":"Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab\u2013bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study","volume":"24","author":"Zeng","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib219","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2473165","article-title":"MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"14","author":"Llopiz","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib220","doi-asserted-by":"crossref","first-page":"90390","DOI":"10.18632\/oncotarget.20153","article-title":"Combining des-gamma carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.compbiomed.2025.111120_bib221","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4149\/neo_2012_020","article-title":"Diagnostic performance of des-gamma-carboxy prothrombin (DCP) for hepatocellular carcinoma: a bivariate meta-analysis","volume":"59","author":"Gao","year":"2012","journal-title":"Neoplasma"},{"key":"10.1016\/j.compbiomed.2025.111120_bib222","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12032-009-9215-y","article-title":"GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population","volume":"27","author":"Hu","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib223","first-page":"811","article-title":"Diagnostic value of Glypican-3 for hepatocellular carcinomas","volume":"19","author":"ElSaadny","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.compbiomed.2025.111120_bib224","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012954","article-title":"Prognostic value of osteopontin in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"97","author":"Sun","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.compbiomed.2025.111120_bib225","first-page":"153","article-title":"Dickkopf-1 and amphiregulin as novel biomarkers and potential therapeutic targets in hepatocellular carcinoma","volume":"13","author":"Awad","year":"2019","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib226","article-title":"Diagnostic accuracy of midkine for hepatocellular carcinoma: a meta-analysis","volume":"8","author":"Zhang","year":"2020","journal-title":"Mol. Genet. Genomic. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib227","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4254\/wjh.v9.i9.469","article-title":"Annexin A2as abiomarker for hepatocellular carcinoma in Egyptian patients","volume":"9","author":"Shaker","year":"2017","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib228","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1007\/s13277-013-1563-8","article-title":"Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis","volume":"35","author":"Gan","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib229","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.compbiomed.2025.111120_bib230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma\u2014An update","volume":"9","author":"Gellrich","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.compbiomed.2025.111120_bib231","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","article-title":"The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies","volume":"6","author":"Shi","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib232","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100777","article-title":"Safety and long-term outcome of intratumoral injection of ok432-stimulated dendritic cells for hepatocellular carcinomas after radiofrequency ablation","volume":"13","author":"Kitahara","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib234","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/bjc.2015.430","article-title":"A phase I\/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma","volume":"113","author":"Lee","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.compbiomed.2025.111120_bib235","article-title":"Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy","volume":"95","author":"Zhulai","year":"2021","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib236","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820967454","article-title":"Wang X. a systematic review and meta-analysis of immune-related adverse events of anti-PD-1 drugs in randomized controlled trials","volume":"19","author":"Wang","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.111120_bib237","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib238","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"KEYNOTE-240 investigators. pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib239","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"6230","key":"10.1016\/j.compbiomed.2025.111120_bib240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib241","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J."},{"key":"10.1016\/j.compbiomed.2025.111120_bib242","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"7385","key":"10.1016\/j.compbiomed.2025.111120_bib243","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib244","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib245","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pharmthera.2013.12.015","article-title":"Epigenetic drugs as immunomodulators for combination therapies in solid tumors","volume":"142","author":"Sigalotti","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"21","key":"10.1016\/j.compbiomed.2025.111120_bib246","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1002\/cam4.3410","article-title":"Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"issue":"6316","key":"10.1016\/j.compbiomed.2025.111120_bib247","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib248","doi-asserted-by":"crossref","first-page":"25","DOI":"10.20892\/j.issn.2095-3941.2022.0449","article-title":"Angiogenesis in hepatocel lular carcinoma: mechanisms and anti-angiogenic therapies","volume":"20","author":"Yao","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"385","key":"10.1016\/j.compbiomed.2025.111120_bib249","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.111120_bib250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immuno therapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.111120_bib251","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.111120_bib252","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"issue":"7","key":"10.1016\/j.compbiomed.2025.111120_bib253","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"ORIENT-32 study group. sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.111120_bib254","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1158\/1078-0432.CCR-20-4706","article-title":"Atezolizumab plus bevaci zumab: a novel breakthrough in hepatocellular carcinoma","volume":"27","author":"Castet","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4_ Suppl","key":"10.1016\/j.compbiomed.2025.111120_bib255","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.2022.40.4_suppl.423","article-title":"Ramucirumab for patients with advanced hepatocellular carcinoma and elevated \u03b1-fetoprotein following a non-sorafenib based first-line therapy: final results from an expansion cohort of REACH-2","volume":"40","author":"Finn","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10126","key":"10.1016\/j.compbiomed.2025.111120_bib256","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.compbiomed.2025.111120_bib257","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jvir.2018.01.769","article-title":"Predicting treatment response to intra-arterial therapies for he patocellular carcinoma with the use of supervised machine learning-an artificial intelligence concept","volume":"29","author":"Abajian","year":"2018","journal-title":"J. Vasc. Intervent. Radiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib258","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ebiom.2019.10.057","article-title":"Machine learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study","volume":"50","author":"Ji","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.compbiomed.2025.111120_bib259","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.3390\/cancers12102791","article-title":"Novel model to predict HCC recurrence after liver transplantation obtained using deep learning: a multicenter study","volume":"12","author":"Nam","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.compbiomed.2025.111120_bib260","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/hep.31207","article-title":"Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides","volume":"72","author":"Saillard","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.compbiomed.2025.111120_bib261","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00330-019-06318-1","article-title":"Residual convolutional neural network for predicting response of transarterial chemo embolization in hepatocellular carcinoma from CT imaging","volume":"30","author":"Peng","year":"2020","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib262","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.ultrasmedbio.2020.05.010","article-title":"Tumor vascular networks depicted in contrast-enhanced ultrasound images as a predictor for transarterial chemoembolization treatment response","volume":"46","author":"Oezdemir","year":"2020","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.compbiomed.2025.111120_bib263","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jama.2016.2420","article-title":"Data sharing: an ethical and scientific imperative","volume":"315","author":"Bauchner","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.compbiomed.2025.111120_bib264","first-page":"N","article-title":"The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives","volume":"11","author":"Celsa","year":"2025","journal-title":"Hepat. Res."},{"key":"10.1016\/j.compbiomed.2025.111120_bib265","series-title":"Regulatory Considerations on Artificial Intelligence for Health","year":"2023"}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525014738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525014738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:49:28Z","timestamp":1762271368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482525014738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":265,"alternative-id":["S0010482525014738"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.111120","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancement in hepatocellular carcinoma research: Biomarkers, therapeutics approaches and impact of artificial intelligence","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.111120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111120"}}